1-2 of 2
Nathan Gossai
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling

Peter Bader, Emilia Salzmann-Manrique, Adriana Balduzzi, Jean-Hugues Dalle, Ann E. Woolfrey, Merav Bar, Michael R. Verneris, Michael J. Borowitz, Nirali N. Shah, Nathan Gossai, Peter J. Shaw, Allen R. Chen, Kirk R. Schultz, Hermann Kreyenberg, Lucia Di Maio, Gianni Cazzaniga, Cornelia Eckert, Vincent H. J. van der Velden, Rosemary Sutton, Arjan Lankester, Christina Peters, Thomas E. Klingebiel, Andre M. Willasch, Stephan A. Grupp, Michael A. Pulsipher
Journal: Blood Advances
Blood Adv (2019) 3 (21): 3393–3405.
https://doi.org/10.1182/bloodadvances.2019000449
Published: 2019
Includes: Supplemental data
Journal Articles

Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia

Clinical Trials & Observations
Amy K. Keating, Nathan Gossai, Christine L. Phillips, Kelly Maloney, Kristen Campbell, Andrew Doan, Deepa Bhojwani, Michael J. Burke, Michael R. Verneris
Journal: Blood Advances
Blood Adv (2019) 3 (13): 1926–1929.
https://doi.org/10.1182/bloodadvances.2018025726
Published: 2019